Sublingual immunotherapy: No more doubts

European Annals of Allergy and Clinical Immunology

Volumn 37, Issue 8, 2005, Pages 314-320

  Passalacqua, G ^b   Lombardi, C ^a   Guerra, L ^b   Compalati, E ^b   Fumagalli, F ^b   Canonica, G W ^b  

^a S Orsola Hospital   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; GRASS POLLEN EXTRACT;

ASTHMA; BIRCH; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GRASS; HEADACHE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; META ANALYSIS; MITE; PARIETARIA; PATIENT COMPLIANCE; RESPIRATORY TRACT ALLERGY; REVIEW; RHINITIS; SYSTEMATIC REVIEW; URTICARIA; VACCINATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 27744439161     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;i:1572-1573.
2. Black JH. The oral administration of pollen. J Lab Clin Med 1927; 12: 1156
3. Herxeimer H. Bronchial hypersensitization and hyposensitization in man. Int Arch Allergy Appl Immunol 1951; 40: 40-57
4. Taylor G, Shivalkar PR. Local nasal desensitization in allergic rhinitis. Clin Allergy 1972; 2: 125-126
5. Taudorf E, Weeke B. Orally administered grass pollen. Allergy 1983; 38: 561-564
6. Committee on the safety of medicines. CSM update. Desensitizing vaccines. Br Med J 1986; 293: 948
7. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987; 79: 660-677
8. Reid MJ, Lockey RF, Turkeltaub PC, Platt-Mills TAE. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993; 92: 6-15
9. EAACI Immunotherapy position paper. Malling HJ & Weeke B edts, Allergy 1993; 48.
10. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986; 16: 483-491
11. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Bousquet J, Lockey R, Malling HJ edts. Allergy 1998: 53 suppl.
12. EAACI Position Paper on local immunotherapy. Malling HJ edt. Allergy 1998; 53: 933.
13. Allergic Rhinits and its Impact on Asthma. Bousquet J and Van Cauwenberge P edts. J Allergy Clin Immunol 2001; 108(5 suppl): S146-S150
14. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol 1990; 18: 277-284.
15. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49: 309-313.
16. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995; 23: 173-178
17. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in parietaria pollen induced rhinitis: a double blind study. J Invest Allergol Clin Immunol 1995; 5: 25-30
18. Hirsch T, Sahn M, Leupold W. Double blind placebo controlled study of sublingual immunotherapy with house dust mite extracts in children. Pediatr Allergy Immunol 1997; 8: 21-27
19. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual swallow immunotherapy: a double blind placebo controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998; 53: 493-498
20. Horak F, Stubner UE, Berger U, Marks B, Toth J, Jager S,. Immunotherapy with sublingual birch pollen extract: a short term double blind study. J Invest Allergol Clin Immunol 1998; 8: 165-171.
21. Vourdas D, Syrigou E, Potamianou P et al. Double blind placebo controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998; 53: 662-671.
22. Hordijk GJ, Antwelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract: a double blind placebo controlled study. Allergol Immunopathol 1998; 26: 234-240
23. Passalacqua G, Albano M, Fregonese L et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite induced rhinoconjunctivitis. Lancet 1998; 351: 629-632.
24. Passalacqua G, Albano M, Riccio AM et al. Clinical and immunological effects of a rush sublingual immunotherapy to parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999; 104: 964-968
25. Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double blind placebo controlled study. Allergy 1999; 54: 249-260
26. Purello D'Ambrosio F, Gangemi S, Isola S et al Sublingual immunotherapy: a double blind placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy 1999; 54: 968-973
27. Pradalier A, Basset D, Claudel A et al. Sublingual swallow immunotherapy (SLIT) with a standardized five grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54: 819-828
28. La Rosa M, Ranno C, André C et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104: 425-432
29. Guez S, Vatrinet C, Fadel R, André C. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double blind placebo controlled study. Allergy 2000; 55: 369-375
30. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunological effects of longterm sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy 2000; 55: 842-849.
31. Caffarelli C, Sensi LG, Marcucci F, Cavagni C. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy. 2000; 55: 1142-1147.
32. Ariano R. Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol (Madr). 2001; 29: 238-244.
33. Bahcecilier NN, Isik U, Barlan IB, Basaran N. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol. 2001; 32: 49-55.
34. Voltolini S, Modena P, Minale P et al. Sublingual immunotherapy in tree pollen allergy. Double blind, placebo controlled study with a biologically standardized extract of treee pollen (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 2001; 29: 103-110
35. Lima MT, Wilson D, Pitkin L et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32: 507-514
36. Mortemousque B, Bertel F, De Casamayor J, Verin P, Colin J. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2003; 33: 464-469.
37. Andrè C, Perrin-Fayolle M, Grosclaude M et al. A double blind placebo controlled evaluation of SLIT with a standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003; 131: 111-118
38. Ippoliti F, De Sanctis W, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14: 216-221.
39. Pajno G, Vita D, Caminiti D, Parmiani S, BArberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy. 2003 Dec;33(12):1641-7.
40. Wuthrich B, Bucher Ch, Jorg W, Bircher A, Eng P, Schneider Y, Schnyder F, Eigenmann P, Senti G. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol. 2003;13(3):145-8.
41. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, Delecluse P, Andre C. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy. 2004 May;59(5):491-7.
42. Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T, Braun W. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy. 2004 May;59(5):498-504.
43. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane review). Cochrane Database Syst Rev. 2003; (2): CD002893
44. Lombardi C, Gargioni S, Venturi S, Zoccali P, Canonica GW, Passalacqua G. Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity. J Invest Allergol Clin Immunol 2001; 11: 41-45.
45. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study with SLIT in real life: clinical efficacy and more. Allergy 2004, in press.
46. Pajno GB, Passalacqua G, Vita D, Parmiani S, Barberio G. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004; 59: 883-7
47. Patriarca G, Nucera E, Pollastrini E, Roncallo C, Buonomo A, Bartolozzi F, De Pasquale T, Gasbarrini G, Schiavino D. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg. 2002; 95: 956-960
48. Cistero Bahima A, Sastre J, Enrique E, Fernandez M, Alonso R, Quirce S, Gandarias B, Parmiani S, Rico P. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol. 2004; 14: 17-25.
49. Quirino T, Iemoli E, Siciliani E, Parmiani S. Sublingual vs injective immunotherapy in grass pollen allergic patients: a double blind double dummy study. Clin Exp Allergy 1996; 26: 1253-1261
50. Khinchi MS, Poulsen LK, Carat F, Andrè C, Hansen AB, Malling H-J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen sepcific immunotherapy. A randomized placebo controlled, double blind, double dummy study. Allergy 2004; 59: 45-53
51. Tinkelman DG, Cole WQ, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol. 1995; 95: 8-14.
52. Lin MS, Tanner E, Lynn J, Friday GA. Nonfatal systemic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71: 557-562
53. Ostergaard PA, Kaad PH, Kristensen T. A prospective study on the safety of immunotherapy in children with severe asthma. Allergy. 1986; 41: 588-593.
54. Stewart GE, Lockey RF Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol. 1992; 90: 567-578.
55. Lockey RF, Nikoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001; 87 (1 supp): S46-S55
56. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121: 229-234
57. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children Allergy 1999; 54: 1110-1113
58. Lombardi C, Gargioni S, Melchiorre A et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001; 56: 889-892
59. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of Sublingual immunotherapy in children with asthma. Paediatr Drugs. 2003; 5: 777-81
60. Agostinis F, Tellarini L, Falagiani P, Canonica GW, Passalacqua G. Safety of SLIT in very young children. Allergy 2004 in press
61. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post-marketing surveillance study. Allergol Immunopathol (Madr). 2004; 32: 76-81.
62. Lombardi C, Canonica GW, Passalacqua G. Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. Allergy 2000; 55: 677-678
63. Grosclaude M, Bouillot P, Alt R et al. Safety of various dosage regimens during induction of sublingual immunotherapy. Int Arch Allergy Immunol 2002; 129: 248-253
64. Frati F, Sensi L, Di Rienzo V, Senna GE, Incorvaia C, Marcucci F. A model for management of sublingual immunotherapy. Allerg Immunol (Paris). 2003 Feb; 35(2): 56-60
65. Passalacqua G, Canonica GW. Long lasting efficacy of specific immunotherapy. Allergy 2002; 57: 275-276.
66. Di Rienzo V, Marcucci F, Puccinelli P et al. Long lasting effect of sublingual immunotherapy in children with asthma due to house dust mites: a ten-year prospective study. Clin Exp Allergy 2003; 33: 206-210
67. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-256.
68. Novembre E, Galli E, LAndi F, Caffarelli C, Pifferi M et al. Co seasonal SLIT reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol in press.
69. Pajno G, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31: 1392-1397.
70. Purello D'Ambrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001; 31: 1295-1302.
71. Tinkelman D, Smith F, Cole WQ 3rd, Slik HJ. Compliance with an allergen immunotherapy regimen. Ann Allergy Asthma Immunol 1995; 74(3): 241-246.
72. Lower T, Hensy J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy. 1993; 70: 480-482.
73. Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW. Passalacqua G. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004; 113: 1219-20
74. Till SJ, Francio JN, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113: 1025-1034
75. Marcucci F, Frati F, Sensi L et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy. 2003; 58: 657-662.
76. Bagnasco M, Mariani G, Passalacqua G et al. Absorption and distribution kinetics of the mayor Parietaria allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997; 100: 121-129
77. Bagnasco M, Passalacqua G, Villa G et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31: 54-60
78. Nelson HS. Advances in upper airway disease and allergen immunotherapy. J Allergy Clin Immunol 2003; 111: S793-798
79. Sopo SM, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Chil 2004; 89: 620-4.